Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03406780 · ClinicalTrials.gov registry record · Phase 2
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
A Phase 2 study, sponsored by Capricor.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03406780 is a Phase 2 study that has completed, run by Capricor. The registered enrollment target is 20 participants.
The verdict
NCT03406780, a Phase 2 study, has completed, sponsored by Capricor.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
HOPE-2 is a double-blind clinical trial evaluating the safety and efficacy of a cell therapy called CAP-1002 in study participants with Duchenne Muscular Dystrophy (DMD). Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either CAP-1002 or placebo every 3 months for a total of 4 doses during a 12-month period.
Interventions
- DRUG Placebo
- BIOLOGICAL CAP-1002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-04-04 |
| Est. Completion | 2020-03-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03406780
The ClinicalTrials.gov registry entry for NCT03406780 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Capricor, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03406780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03406780 about?
NCT03406780 is a clinical study titled "A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy". HOPE-2 is a double-blind clinical trial evaluating the safety and efficacy of a cell therapy called CAP-1002 in study participants with Duchenne Muscular Dystrophy (DMD). Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either CAP-10...
What is the current status of trial NCT03406780?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2018-04-04. Estimated completion is 2020-03-10.
What interventions are being tested in trial NCT03406780?
The interventions under investigation include: Placebo (DRUG), CAP-1002 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03406780?
This trial is sponsored by Capricor, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.